Home
Storia in 1 fonti
Cenexi recovery, new product launches and capacity additions power Gland Pharma outlook
Gland Pharma stock surged to a 52-week high following robust March quarter and full-year results. Its European unit, Cenexi, is improving profitability. Future growth is anticipated from capacity expansions and new product lines. The company's contract development and manufacturing business is also expanding. Investors are watching Gland Pharma's growth prospects.
Raccontata da
economictimes.indiatimes.com
- ·
Gland Pharma shares jump 11% as Q4 profit soars 97% YoY, co announces Rs 20/share final dividend
Shares of Gland Pharma rallied on Monday after the company reported a 97% YoY surge in Q4 profit and strong revenue growth, driven by its CDMO business. The board also announced a…
- ·
Cenexi recovery, new product launches and capacity additions power Gland Pharma outlook
Gland Pharma stock surged to a 52-week high following robust March quarter and full-year results. Its European unit, Cenexi, is improving profitability. Future growth is…